Viking Therapeutics: An In-depth Look at the Explosive Growth in the Weight Loss Drug Market
Monday, 8 April 2024, 09:55
Weight loss drugs
Shares of Viking Therapeutics have soared on promising data from clinical trials of its weight loss drug candidate VK-2735. The weight loss drug market is forecasted to grow to $100 billion annually by 2030, driven by high demand and limited supply.
Eli Lilly and Novo Nordisk are staying ahead
Despite Viking's success, Eli Lilly and Novo Nordisk are conducting late-stage trials for potentially more effective weight loss candidates. These pharma giants have the resources and experience to maintain their dominance in the market.
- Conclusion: While Viking Therapeutics shows potential in the weight loss drug market, competition and long road to commercialization may hinder its growth. Investors should carefully evaluate the risks before considering investing in Viking stock.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.